Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Consolidation in Stage III NSCLC
NCT04085250Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2019
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Started Nov 2019; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04085250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04085250.